SCHEMBL4589980

SCHEMBL4589980

NCCCC[C@H](NC(=O)[C@@H](Cc1c[nH]cn1)NC(=O)CN)C(=O)[O-].NCCCC[C@H](NC(=O)[C@@H](Cc1c[nH]cn1)NC(=O)CN)C(=O)[O-].[Mn+2]

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.54
MMP1 P03956 1/20 0.36
GHSR Q92847 4/20 0.36
CALCRL Q16602 2/20 0.33
NMT2 O60551 2/20 0.32
NMT1 P30419 2/20 0.32
ECE1 P42892 1/20 0.31
CPB1 P15086 1/20 0.31
CPB2 Q96IY4 1/20 0.31
PRSS1 P07477 1/20 0.30
PRSS2 P07478 1/20 0.30
PRSS3 P35030 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4587124 1.00 SLC15A2 (0.54) SLC15A2MMP1GHSRCALCRLNMT2
SCHEMBL2815083 0.98 SLC15A2 (0.54) SLC15A2MMP1GHSRCALCRLNMT2
SCHEMBL2243005 0.98 SLC15A2 (0.54) SLC15A2MMP1GHSRCALCRLNMT2
SCHEMBL9616734 0.96 SLC15A2 (0.52) SLC15A2MMP1GHSRCALCRLNMT2
SCHEMBL9616919 0.94 SLC15A2 (0.52) SLC15A2MMP1GHSRCALCRLNMT2
SCHEMBL5089363 0.90 SLC15A2 (0.44) SLC15A2MMP1GHSRCALCRLNMT2
SCHEMBL259084 0.89 SLC15A2 (0.64) SLC15A2GHSRCALCRLECE1
SCHEMBL5598418 0.89 SLC15A2 (0.64) SLC15A2GHSRCALCRLECE1
SCHEMBL10595108 0.89 SLC15A2 (0.64) SLC15A2GHSRCALCRLECE1
SCHEMBL8832939 0.89 SLC15A2 (0.64) SLC15A2GHSRCALCRLECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 US disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 SLC15A2 2656/4885MMP1 625/4885GHSR 1411/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R SLC15A2 1582/4885MMP1 1224/4885GHSR 748/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 SLC15A2 2656/4885MMP1 625/4885GHSR 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.